{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:58Z","timestamp":1792184698205,"version":"4.4.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: Plasma concentrations of procollagen peptides are decreased in osteogenesis imperfecta (OI), whereas other bone formation markers may be increased. We examined the utility of combining these markers in the diagnosis of OI in adults.<\/jats:p>\n               <jats:p>Methods: We measured plasma concentrations of procollagen-1 N-peptide (P1NP), osteocalcin, and bone alkaline phosphatase in 24 patients with nondeforming OI, 25 patients with low bone mass due to other causes, and 38 age- and sex-matched controls. The discriminant ability of various test combinations was assessed by the construction of ROC curves.<\/jats:p>\n               <jats:p>Results: The median (range) ratio of osteocalcin to P1NP was significantly greater in patients with type I OI [1.75 (0.80\u20133.86)] than in controls [0.59 (0.34\u20130.90)] and patients with other causes of low bone mass [0.48 (0.05\u20131.38); P &amp;lt;0.0001]. This ratio allowed nearly complete differentiation between healthy controls and patients with type I OI, but not patients with type IV OI. With a cutoff of 0.97 for osteocalcin:P1NP, the sensitivity and specificity were maximized at 95% (95% CI 76%\u2013100%) and 88% (69%\u201397%), respectively, for patients with other causes of low bone mass vs those with type I OI only. For patients with other causes of low bone mass vs all OI patients, sensitivity and specificity were 83% (63%\u201395%) and 88% (69%\u201397%), respectively. The addition of bone alkaline phosphatase data did not improve the discriminant ability of the osteocalcin:P1NP ratio.<\/jats:p>\n               <jats:p>Conclusions: The osteocalcin:P1NP ratio is a sensitive and specific test for type I OI in adults, but it has less utility in the diagnosis of other types of nondeforming OI.<\/jats:p>","DOI":"10.1373\/clinchem.2006.083055","type":"journal-article","created":{"date-parts":[[2007,4,13]],"date-time":"2007-04-13T20:25:27Z","timestamp":1176495927000},"page":"1109-1114","source":"Crossref","is-referenced-by-count":22,"title":["Bone Formation Markers in Adults with Mild Osteogenesis Imperfecta"],"prefix":"10.1093","volume":"53","author":[{"given":"Tim","family":"Cundy","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Horne","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bolland","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Gamble","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Davidson","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, Auckland City Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,6,1]]},"reference":[{"key":"2020022802444727400_R1","doi-asserted-by":"crossref","unstructured":"Shapiro JR. Osteogenesis imperfecta and other defects of bone development as occasional causes of adult osteoporosis. Marcus R Feldman D Kelsey J eds. Osteoporosis, 2nd ed2001:271-301 Academic Press San Diego, CA. .","DOI":"10.1016\/B978-012470862-4\/50051-9"},{"key":"2020022802444727400_R2","doi-asserted-by":"crossref","unstructured":"Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet1979;16:101-116.","DOI":"10.1136\/jmg.16.2.101"},{"key":"2020022802444727400_R3","doi-asserted-by":"crossref","unstructured":"Byers PH, Wallis GA, Willing MC. Osteogenesis imperfecta: translation of mutation to phenotype. J Med Genet1991;28:433-442.","DOI":"10.1136\/jmg.28.7.433"},{"key":"2020022802444727400_R4","unstructured":"Delmas PD. Biochemical markers for the assessment of bone turnover. Riggs BL Melton LJ eds. Osteoporosis: Etiology, Diagnosis and Management 2nd ed. 1995:319-333 Lippincott-Raven Philadelphia, PA. ."},{"key":"2020022802444727400_R5","unstructured":"Whyte MP. Osteogenesis imperfecta. Favus MJ eds. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed2003:470-473 American Society for Bone and Mineral Research Washington, DC. ."},{"key":"2020022802444727400_R6","doi-asserted-by":"crossref","unstructured":"Lund AM, Hansen M, Kollerup G, Juul A, Teisner B, Skovby F. Collagen-derived markers of bone metabolism in osteogenesis imperfecta. Acta Paediatr1998;87:1131-1137.","DOI":"10.1111\/j.1651-2227.1998.tb00920.x"},{"key":"2020022802444727400_R7","doi-asserted-by":"crossref","unstructured":"Brenner RE, Schiller B, Vetter U, Ittner J, Teller WM. Serum concentrations of procollagen I C-terminal propeptide, osteocalcin, and insulin-like growth factor-I in patients with non-lethal osteogenesis imperfecta. Acta Paediatr1993;82:764-767.","DOI":"10.1111\/j.1651-2227.1993.tb12554.x"},{"key":"2020022802444727400_R8","doi-asserted-by":"crossref","unstructured":"Cepollaro C, Gonnelli S, Pondrelli C, Montagnani A, Martini S, Bruni D, et al. Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters. Calcif Tissue Int1999;65:129-132.","DOI":"10.1007\/s002239900670"},{"key":"2020022802444727400_R9","doi-asserted-by":"crossref","unstructured":"Minisola S, Piccioni AL, Rosso R, Romagnoli E, Pacitti MT, Scarnecchia L, et al. Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta. Metabolism1994;43:1261-1265.","DOI":"10.1016\/0026-0495(94)90220-8"},{"key":"2020022802444727400_R10","doi-asserted-by":"crossref","unstructured":"Braga V, Gatti D, Rossini Colapietro F, Battaglia E, Viapiana O, et al. Bone turnover markers in patients with osteogenesis imperfecta. Bone2004;34:1013-1016.","DOI":"10.1016\/j.bone.2004.02.023"},{"key":"2020022802444727400_R11","unstructured":"Wenstrup RJ, Willing MC, Starman BJ, Byers PH. Distinct biochemical phenotypes predict clinical severity in nonlethal variants of osteogenesis imperfecta. Am J Hum Genet1990;46:975-982."},{"key":"2020022802444727400_R12","unstructured":"Kramer MS. Clinical Epidemiology and Biostatistics: A Primer for Clinical Investigators and Decision-Makers1988:286pp Springer-Verlag Berlin, Germany. ."},{"key":"2020022802444727400_R13","doi-asserted-by":"crossref","unstructured":"DeLong ER, DeLong DM, Clarke-Paerson DL. Comparing the areas under two or more correlated receiver operator curves: a nonparametric approach. Biometrics1998;44:837-845.","DOI":"10.2307\/2531595"},{"key":"2020022802444727400_R14","unstructured":"Weinstein MC, Fineberg HV. Clinical Decision Analysis1980:351pp WB Saunders Philadelphia, PA. ."},{"key":"2020022802444727400_R15","doi-asserted-by":"crossref","unstructured":"Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet2004;363:1377-1385.","DOI":"10.1016\/S0140-6736(04)16051-0"},{"key":"2020022802444727400_R16","doi-asserted-by":"crossref","unstructured":"Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int2000;11:281-294.","DOI":"10.1007\/s001980070116"},{"key":"2020022802444727400_R17","doi-asserted-by":"crossref","unstructured":"Paterson CR, McAllion SJ. Osteogenesis imperfecta in the differential diagnosis of child abuse. BMJ1989;299:1451-1454.","DOI":"10.1136\/bmj.299.6713.1451"},{"key":"2020022802444727400_R18","doi-asserted-by":"crossref","unstructured":"Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget\u2019s disease of bone. Bone2004;35:224-230.","DOI":"10.1016\/j.bone.2004.03.023"},{"key":"2020022802444727400_R19","doi-asserted-by":"crossref","unstructured":"Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone2000;26:581-589.","DOI":"10.1016\/S8756-3282(00)00269-6"},{"key":"2020022802444727400_R20","doi-asserted-by":"crossref","unstructured":"Boyde A, Travers R, Glorieux FH, Jones SJ. The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif Tissue Int1999;64:185-190.","DOI":"10.1007\/s002239900600"},{"key":"2020022802444727400_R21","doi-asserted-by":"crossref","unstructured":"Rauch F, Land C, Cornibert S, Schoenau E, Glorieux FH. High and low density in the same bone: a study on children and adolescents with mild osteogenesis imperfecta. Bone2005;37:634-641.","DOI":"10.1016\/j.bone.2005.06.007"},{"key":"2020022802444727400_R22","unstructured":"Steinmann B, Eyre DR, Shao P. Urinary pyridinoline cross-links in Ehlers-Danlos syndrome type VI. Am J Hum Genet1995;57:1505-1508."}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/53\/6\/1109\/32688263\/clinchem1109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/53\/6\/1109\/32688263\/clinchem1109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T02:46:39Z","timestamp":1582857999000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/53\/6\/1109\/5627555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,1]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2007,6,1]]},"published-print":{"date-parts":[[2007,6,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2006.083055","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,6,1]]},"published":{"date-parts":[[2007,6,1]]}}}